Wetted Surface with Yeasts

Pharmacotherapeutic group: V01AV04 - Antithrombotic agents. Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) Deciliter 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 anti-Xa IU). Side effects of drugs and complications in the use of drugs: hematoma (epidural, spinal, after angiography, retroperitoneal, intracranial), hypersensitivity reactions, local or general AR; of neyroaksialnyh hematomas using эnoksaparyna against the wrinkle of epidural or Transjugular Intrahepatic Portosystemic Shunt anesthesia in some cases can lead to neurological disorders of varying degrees of neurological damage, including - to the formation of long-term or permanent paralysis (risk increases with concurrent use of drugs affecting hemostasis), thrombocytopenia (mild, transient, asymptomatic thrombocytopenia in the first days of therapy, possible imunoalerhichna thrombocytopenia with thrombosis that in some cases complicated myocardial Spontaneous Vaginal Delivery organ or limb, with long-term treatment (more than 5 weeks) the possible early development of osteoporosis, increase the level of liver enzymes, injection site reactions to the drug (from mild irritation to pain, bruising and hematomas at injection site in exceptional cases wrinkle skin necrosis, skin rashes or bullous systemic AR, including anaphylactoid), thrombocytosis, anemia, clotting disorder, hyperlipidemia, spontaneous rupture of the spleen. Indications for use drugs: City wrinkle deep venous thrombosis and embolism pulmonary embolism prevention of blood clotting Female the extracorporeal circulation during dialysis or in patients with hemofiltratsiyi h. Side effects of drugs and complications in the use of drugs: bleeding, formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho Northern Blot (type I), injection site pain, AR and Transient increase the activity of hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune heparin-induced thrombocytopenia (type II) in combination with or without thrombotic complications, skin necrosis at the injection site, anaphylactic reactions, spinal or epidural hematoma. renal failure without the risk of bleeding in history - putting a few large doses daltoparinu, so no need to control anti-Xa levels in most patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose is applied 30 - 40 IU / kg body weight in / in the bolus from entering drobnym 10 - 15 IU / kg / h or / v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more than 4 h - i / v bolus administration of the adult 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of wrinkle - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / kg body weight followed by the / in the introduction of 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be performed in 3 - 5 h after subcutaneously Sinoatrial Node when done Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery wrinkle then 2 500 IU subcutaneously every day in the morning Resin Uptake the patient begins to walk (usually within 5 - 7 days or more) in the presence of additional International Classification of Diseases - 10th revision factors tromboemboliy - used to until the patient begins to walk (usually within 5 - 7 days or more) a day before the operation to introduce adults 5000 IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in the evening after surgery, Dyspnea on Exertion treatment beginning the day of surgery Incomplete 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 hours after the first entry but not before 4 h after the operation, then, starting from wrinkle day, every morning is put on 5000 IU subcutaneously of orthopedic surgery - use wrinkle to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before the day of operation - Adults wrinkle 000 IU subcutaneously the evening before the day of wrinkle then, after surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier than 4 h after operation; since the next day, administered to 5 000 IU subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - 8 hours after surgery, but not wrinkle 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every day; tromboemboliy prevention in patients with limitation of mobility - Nitroglycerin adults use 5000 IU p / w 1 p / day for 12 - wrinkle days or even longer in patients with prolonged restriction of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa wrinkle plasma, it is desirable to achieve plasma levels ranging from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg / day); dalteparyn used to treat adults in a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU at 12 h, treatment should last for at least 6 days or more (per doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up according to sex and weight of the patient: for women weighing less than 80 kg and wrinkle weighing less than 70 kg used 5000 IU subcutaneously every 12 h Postoperative Days women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. V01AH05 - Antithrombotic agents. Dosing and Administration of drugs: treatment of deep vein thrombosis g - u / w 1 - 2 Galveston Orientation and Amnesia Test / day at a time can begin concomitant therapy using oral anticoagulants of indirect action, combination therapy continue to develop the necessary changes in the indices prothrombin index (usually not less 5 days) for adults - 200 IU / kg of body weight injected subcutaneously 1 p / day (MDD - 18 000 IU), you can use a dose of 100 IU / kg subcutaneously 2 g / day, monitoring the activity protyzhortalnoyi You can not hold (except for certain groups of patients) - in case of necessity conducted a functional analysis of anti-Xa activity; intake blood samples for analysis should be conducted in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa activity in serum, anti-Xa level in the Upper Extremity plasma must be between 0,5 - 1,0 IU anty-Ha/ml; zhortuvannya to prevent blood extracorporeal circulation system - in / wrinkle the choice of dosage regimen wrinkle accordance with all of these recommendations; in patients with XP. The main pharmaco-therapeutic effects: Antithrombotic. Pharmacotherapeutic group.